Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentacel + Menactra
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pentacel + Menactra refers to the concomitant administration of two separate vaccines developed by Sanofi Pasteur. **Pentacel** is a pentavalent combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens (DTaP), inactivated poliovirus (IPV), and a *Haemophilus influenzae* type b (Hib) conjugate. It is indicated for active immunization against these five diseases in infants and children. **Menactra** is a quadrivalent meningococcal conjugate vaccine (MCV4) that provides protection against *Neisseria meningitidis* serogroups A, C, Y, and W-135. The co-administration of these vaccines is often evaluated in clinical settings to ensure that the immunogenicity and safety profiles of each component are maintained when given at the same visit. Both vaccines utilize toxoid and conjugate platforms to induce robust antibody responses in pediatric populations.
- Brand names
- PentacelMenactra
- Other names
- DTaP-IPV/Hib + MCV4Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate Vaccine + Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
02
Targets
Poliovirus capsid proteinsNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Pentacel + Menactra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentacel + Menactra.